Once-Weekly HIV Pill Matches Daily Treatment in Phase III Trial

A once-weekly HIV treatment clears a major clinical test

An international Phase III trial has found that a once-weekly oral HIV treatment performed as well as established daily therapy in adults whose virus was already under control, marking a notable step in the long-running effort to reduce the burden of lifelong medication schedules.

The findings were published in the New England Journal of Medicine and presented at the International AIDS Conference in Rio de Janeiro, according to Medical Xpress. The study, known as ISLEND-1, evaluated a once-weekly tablet combining islatravir and lenacapavir and compared it with standard once-daily treatment in people who had already maintained viral suppression.

For HIV care, that distinction matters. Modern antiretroviral therapy has transformed the infection from a fatal diagnosis into a manageable long-term condition for many patients. But effective treatment still often depends on taking pills every day, year after year, without interruption. Researchers and clinicians have spent years trying to widen the menu of options so treatment can better fit into patients’ lives rather than forcing every patient into the same routine.

What the trial showed

The ISLEND-1 study involved 607 adults across 106 clinical sites in 12 countries. Participants were randomly assigned either to switch to the once-weekly tablet or to remain on their existing daily regimen.

After 48 weeks, the weekly treatment was reported to be noninferior to the standard daily approach. More than 93% of participants in both groups maintained viral suppression. Medical Xpress also reported that no participants receiving the weekly treatment experienced virologic failure during the study period.

That result is important because noninferiority is often the key hurdle for treatment simplification. A new regimen does not necessarily need to outperform a well-established standard to matter clinically. If it can preserve viral suppression while reducing the practical demands of treatment, it can still represent a meaningful advance.

The trial focused on adults whose HIV was already well controlled, so the result does not mean a weekly pill has been proven for every stage of care or every patient population. But for people already stable on therapy, the study suggests a once-weekly oral option could become a credible alternative to daily medication.

Why a weekly pill could matter

The significance of the result is not only pharmacological. It is also social and behavioral. Even when daily HIV treatment is effective and widely available, the routine can carry a psychological and logistical cost. A visible pill schedule can reinforce stigma, while the sheer repetition of daily dosing can contribute to treatment fatigue.

Professor Chloe Orkin of Queen Mary University of London, identified by Medical Xpress as a senior author of the study, said the therapy could ease the burden of lifelong pill-taking, particularly for people dealing with stigma and for patients managing multiple other conditions alongside HIV.

That framing helps explain why researchers continue to pursue longer-acting approaches even after dramatic improvements in HIV drugs over the past two decades. The goal is no longer only viral control. It is also durability, convenience, discretion, and flexibility in real-world use.

A once-weekly oral option may also appeal to people who want something less frequent than a daily tablet but who do not want or cannot easily access injectable treatment. That gives the regimen a potentially important middle position in the treatment landscape: less frequent than standard pills, but still oral and familiar in form.

How the regimen fits into the broader HIV treatment shift

HIV treatment has gradually moved toward simpler, more patient-centered regimens. Earlier eras of care often required larger pill burdens, stricter dosing schedules, and more difficult side-effect tradeoffs. In recent years, treatment has steadily shifted toward fewer drugs in a single tablet, longer-acting formulations, and models of care designed around retention and quality of life.

The weekly islatravir-lenacapavir combination fits squarely within that trend. It reflects a broader industry and research push to lower the friction of chronic disease management without giving up clinical control. If approved and adopted, a regimen like this could become especially useful in settings where a weekly cadence is easier to sustain than daily adherence but where regular clinic visits for injections are less practical.

At the same time, weekly treatment is not a universal solution. Patients differ in their preferences, coexisting conditions, drug interactions, and access to care. Some may prefer staying on a daily regimen that is already working well. Others may be better suited to long-acting injectables. The value of the ISLEND-1 result is that it potentially adds another option rather than replacing all others.

What comes next

The reported 48-week data are strong enough to make the weekly regimen one of the more consequential oral treatment developments in HIV care in recent years. But a trial result is not the same as broad clinical rollout. Regulators, guideline bodies, and clinicians will want to examine durability, safety, use across different populations, and how the regimen performs outside tightly monitored trial conditions.

Even so, the headline outcome is clear: a once-weekly oral HIV therapy has now shown that it can match daily treatment in a large international Phase III study among virally suppressed adults.

For patients, that could eventually mean fewer reminders of illness, less pill fatigue, and a treatment schedule that is easier to fit into ordinary life. For the field, it is another sign that the future of HIV care is not just about keeping the virus suppressed, but about doing so in ways that are more flexible, more humane, and more sustainable over decades of treatment.

Key takeaways

• The Phase III ISLEND-1 trial studied a once-weekly oral combination of islatravir and lenacapavir.
• The study enrolled 607 adults across 106 clinical sites in 12 countries.
• After 48 weeks, more than 93% of participants in both the weekly and daily treatment groups maintained viral suppression.
• No participants on the weekly regimen experienced virologic failure during the study, according to the supplied source text.
• The result could expand treatment choice for people who want a less frequent oral option.

This article is based on reporting by Medical Xpress. Read the original article.